(Q43846394)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Geoffrey I Shapiro

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jeffrey W Clark

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Bruce E Johnson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

24 June 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24963024%20AND%20SRC:MED&resulttype=core&format=json

An evaluation of phase I clinical trial designs in the continuous dose-response setting

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Translation of innovative designs into phase I trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Dose escalation methods in phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Dose-finding in phase I clinical trials based on toxicity probability intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Bayesian methods for phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Using toxicity grades in the design and analysis of cancer phase i clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Choice of starting dose and escalation for phase I studies of antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Pharmacologically guided phase I clinical trials based upon preclinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Design of phase I and II clinical trials in cancer: a statistician's view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Design considerations for dose-expansion cohorts in phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Non-publication of large randomized clinical trials: cross sectional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Ethics of phase 1 oncology studies: reexamining the arguments and data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Presentation and subsequent publication rates of phase I oncology clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Phase 1 oncology trials and informed consent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Sequencing technologies - the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163

Rethinking Risk-Benefit Assessment for Phase I Cancer Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJU163